Novel and Combination Therapies for Hepatitis C Virus, An Issue of Clinics in Liver DiseaseDr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV. |
Contents
Summary | |
Viral Kinetics | |
Nonnucleoside Analogue Polymerase Inhibitors | |
Cyclophilin Inhibitors for Hepatitis C Therapy | |
Common terms and phrases
12 weeks 24 weeks 48 weeks achieved SVR adverse events alfa-2a anemia antiviral activity antiviral therapy assays BOC/P/R boceprevir chronic HCV chronic hepatitis cirrhosis clinical combination therapy Cvirus Cyclophilin cyclophilin inhibitor cyclosporine daclatasvir detected direct-acting antiviral drug Engl eRVR erythropoietin etal Gastroenterology genotype 1 infection genotype 1a Gilead Sciences HCV G1 HCV genotype HCV infection HCV RNA HCV RNA levels HCV therapy hepatitis C virus hepatitisC hepatocellular carcinoma Hepatol Hepatology immunosuppressive inthe IU/mL Lawitz lead-in liver transplantation LLOQ mericitabine monotherapy NS5A inhibitor null responders patients with HCV Peg-IFN Peg-IFN/ribavirin PEG/RBV peginterferon alfa-2b peginterferon and ribavirin peginterferon/ribavirin pegylated interferon phase posttransplant potent protease inhibitor quadruple therapy relapse replication response-guided Silibinin sirolimus stopping rules sustained virologic response SVR rates tacrolimus telaprevir treated treatment treatment-experienced patients treatment-naïve patients trials triple therapy TVR/P/R viral load viral response virus infection week 12